AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

The trends on Gift Nifty also indicate a weak start for the Indian benchmark index. The Gift Nifty was trading around 22,960 ...

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

According to experts, the Nifty 50 may attempt to climb above 23,000 again in the upcoming sessions. Above that, ...

Domestic markets expected to open lower, with analysts predicting narrow range trading; macroeconomic data to guide further direction.

If the Nifty 50 closes and sustains above 23,000, the uptrend may extend toward the 23,300–23,500 zone. However, if it ...

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

The views and recommendations given in this article are those of individual analysts. These do not represent the views of ...

Nifty 50 (22,929) and Nifty Bank (49,099) depreciated 2.7 per cent and 2.1 per cent respectively. The futures and options ...

Jay Thakkar recommends buying NTPC Futures, Reliance Futures, and Gujarat Narmada Valley Fertilizers & Chemicals Futures.

The decision to withdraw is based on discussions Co-Diagnostics had with the FDA about the ability to detect a potential deterioration of one component of the test, related to shelf-life stability, it ...